Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long Term Follow-up Study to Evaluate the Safety of RetinoStat in Patients With Age-Related Macular Degeneration

Trial Profile

A Long Term Follow-up Study to Evaluate the Safety of RetinoStat in Patients With Age-Related Macular Degeneration

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Angiostatin-endostatin gene therapy Oxford BioMedica (Primary)
  • Indications Age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Oxford BioMedica
  • Most Recent Events

    • 16 Oct 2018 Planned number of patients changed from 21 to 18.
    • 16 Oct 2018 Planned End Date changed from 1 Nov 2027 to 1 Mar 2029.
    • 16 Oct 2018 Planned primary completion date changed from 1 Nov 2027 to 1 Mar 2029.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top